The Importance of Psychedelic-assisted Therapy
Psychedelic-Assisted Therapy (PAT) is an important new tool to combat the mental health crisis plaguing our society.
The FDA has given PAT “breakthrough therapy” designation which is reserved for therapies that show extreme promise and substantial improvement in treating serious illnesses above and beyond standard treatments.
Enthea was founded in recognition of the healing potential of PAT offers. We strive to address the inequity and inaccessibility that currently exists with PAT, which keep these treatments from those who so desperately need them.
Read on to learn why PAT is an important tool in treating depression, anxiety, PTSD, and other mental health disorders.
Conventional pharmaceutical approaches to mental health treatments have proven to be inadequate for many, even when combined with psychotherapy.
While use of pharmaceutical psychotropic drugs is at an all time high, so too are levels of depression, suicide, and post traumatic stress disorder (PTSD). If these medications were the solution they were hoped to be, we would be seeing a notable decline in these conditions, but unfortunately that is not the case.
The statistics alone are staggering:
Innovation in pharmaceuticals all but stopped in the 1990s with the development of SSRIs. Given the clear inadequacy of standard treatments for mental health disorders, Enthea sees a dire need for a paradigm shift in the treatment of mental health.
Psilocybin and MDMA are trending in the press and on social media, energized by the positive research results using gold standard, double-blinded clinical protocols being carried out at universities like Johns Hopkins University and Stanford University.
Based on such research results, the FDA is expected to approve MDMA in 2024 and psilocybin in 2025 to expand PAT treatment options.
In the meantime, therapists have found that the anesthetic ketamine, when administered in low dosages, is more effective as a psychotherapy aid than current treatments.
Ketamine Assisted Therapy uses ketamine to enhance and deepen the psychotherapeutic process allowing the patient to get to the root of their traumas, and allowing the use of psychotherapy to amplify and prolong the curative effects of ketamine.
When compared with current treatments, ketamine and ketamine-assisted therapy shows great improvements:
The current lack of access to psychedelic-assisted therapy is a real issue for many needing help, and Enthea is striving to bring a solution.
PAT is being recognized as a breakthrough therapy by the FDA and has shown great promise in the treatment of illness such as depression, PTSD, and substance use disorder with greater success than conventional treatments. Ketamine therapy has provided relief for many, while psilocybin and MDMA are on course for approval by the FDA in the near future.
This new approach to mental health care has the potential to help millions of people who have been struggling with their current treatments. If you’d like to find out more how you or your employer can bring this innovative treatment to your organization, contact an Enthea team member today!